Editorial
doi: 10.1093/brain/awf147.
Devic's disease: bridging the gap between laboratory and clinic
- PMID: 12076994
- DOI: 10.1093/brain/awf147
Item in Clipboard
Editorial
Devic's disease: bridging the gap between laboratory and clinic
Brain.
2002 Jul.
No abstract available
Comment on
-
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.Brain. 2002 Jul;125(Pt 7):1450-61. doi: 10.1093/brain/awf151. Brain. 2002. PMID: 12076996 Free PMC article.
Similar articles
-
Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica.Neurosci Lett. 2001 Jul 13;307(2):131-3. doi: 10.1016/s0304-3940(01)01949-8. Neurosci Lett. 2001. PMID: 11427318
-
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice.J Clin Invest. 2006 Sep;116(9):2393-402. doi: 10.1172/JCI28334. J Clin Invest. 2006. PMID: 16955141 Free PMC article.
-
Devic's disease and autoantibodies.Lancet Neurol. 2005 Mar;4(3):136-7. doi: 10.1016/S1474-4422(05)00996-8. Lancet Neurol. 2005. PMID: 15721820 No abstract available.
-
Cytokines and antibodies in myelin oligodendrocyte glycoprotein-induced experimental allergic encephalomyelitis.Res Immunol. 1998 Nov-Dec;149(9):794-804; discussion 847-8, 855-60. doi: 10.1016/s0923-2494(99)80007-8. Res Immunol. 1998. PMID: 9923635 Review. No abstract available.
-
Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.Rev Neurol (Paris). 2018 Dec;174(10):675-679. doi: 10.1016/j.neurol.2018.01.378. Epub 2018 Oct 4. Rev Neurol (Paris). 2018. PMID: 30293882 Review.
Cited by
-
[Multiple sclerosis: potential therapeutic options and update of ongoing studies].Nervenarzt. 2004 Jun;75(6):536-52. doi: 10.1007/s00115-003-1665-4. Nervenarzt. 2004. PMID: 15257377 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
